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ABSTRACT
Malignant pleural mesothelioma is a poorly treated neoplasia arising from the 
pleural mesothelial lining. Here we document that the leaf extract of Cynara scolymus 
exerts broad antitumoral effects both in vitro and in vivo on mesothelioma cell lines. 
We found that Cynara scolymus treatment affects strongly cell growth, migration 
and tumor engraftment of mesothelioma cell lines. Strikingly, dietary feeding with 
Cynara scolymus leaf extract reduces the growth of mesothelioma xenografted 
tumors similarly to pemetrexed, a commonly employed drug in the treatment of 
mesothelioma. In aggregate our findings suggest that leaf extract of Cynara scolymus 
holds therapeutic potential for the treatment of mesothelioma.
INTRODUCTION
Malignant pleural mesothelioma (MPM) is an 
aggressive tumour arising from the mesothelial lining of 
the pleura, which remains compartmentalized for most of 
the disease course [1] [2]. Current therapeutic approaches 
include surgery, radiotherapy and chemotherapy. Cisplatin 
(CDDP) alone or with pemetrexed (PMTX) still represents 
the current standard of care [3] [4] [5]. Similarly to most solid 
tumours, the acquired resistance impedes the success of the 
therapeutic response. Overall patient’s survival ranges from 
8 and 18 months. Furthermore, there is not any diagnostic 
tool that allows an early detection of the disease [2] [6]. 
Given the role played from the asbestos in the etiology of the 
mesothelioma, this tumor is still considered an occupational 
disease [7] [8] [9]. Mesothelioma is an orphan disease 
with an increasing worldwide incidence, especially in the 
developing countries where the asbestos is still exported 
and not banned [9] [10]. After inhalation asbestos fibers 
infiltrate pleural spaces and accumulate in black spots. This 
leads to the induction of pleural fibrosis that might result 
in cancer transformation [11] [12]. Within the last five 
decades, the natural products have continuously contributed 
to drug discovery and development process [13] [14] [15]. 
Increasing evidences have shown that natural products, 
including extracts and isolated chemicals, are multi-targeted 
and can be considered as a model to approach chronic 
diseases such as cancer. Actually, most natural agents do 
not induce high level of toxicity and target simultaneously 
multiple signalling pathways involved in cell growth, 
apoptosis, invasion, angiogenesis and metastasis [16] [17]. 
Since cancer is the result of a deregulation of multiple 
signalling pathways and natural products elicit multi-targeted 
activities, the latter could hold a great potential for treating 
human tumors [18] [6]. The long period between asbestos 
exposure and the development of disease may be a window 
of opportunity for chemoprevention or dietary interventions. 
It has been shown that some natural agents such as coffee, 
resveratrol, curcumin and butein exert anticancer activities 
in mesothelioma cellular systems [2] [10] [19] [19] [20]. 
Observational studies have shown that high adherence to 
a Mediterranean diet, which encompasses a combination 
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of characteristic foods such as fruits, vegetables fresh 
produce, fish and seafood, nuts, legumes/pulses and olive 
oil [21], is associated with a significant reduction in the 
risk of overall cancer mortality (10%), colorectal cancer 
(14%), prostate cancer (4%) and aero digestive cancer 
(56%) [22]. The most diffuse phytochemicals in nature 
are the classes of polyphenols. For long time, polyphenols 
have been considered only for their antioxidants properties. 
Recent data have revealed that polyphenols affect different 
cell signalling pathways. This also occurs through the 
modulation of microRNAs thereby affecting the expression 
of their mRNA targets whose encoded proteins are critical 
components of different pathways [23] [23]. Globe 
artichoke (Cynara scolymus) is a fundamental component of 
Mediterranean diet [24]. It has been reported that the edible 
parts (receptacles with inner and intermediate bracts) and 
leaves of artichokes represent a potent source of polyphenols 
fractions. Recent data have revealed that polyphenols affect 
different cell signalling pathways and exert their anticancer 
effects along the different steps of carcinogenesis [25] 
[26] [27]. Furthermore, the main components of Cynara 
scolymus are caffeoylquinic acid derivatives (cynarin and 
chlorogenic acid), flavonoids (luteolin and apigenin) and 
bitters (cynaropicrin) [28] [29] [28]. Several in vitro and 
in vivo experiments have shown that Cynara scolymus 
exhibits choleretic, hepatoprotective, antibacterial, 
antinflammatory, antithrombotic and hypocoles terolemic 
properties [30] [31] [32] [33]. Artichoke extracts are reported 
to induce apoptosis and cytotoxic effects in cancer cells 
[34] [35] [36]. In the present report we aimed to demonstrate 
the anti-cancer activity of the artichoke leaf extract through 
direct experimental tests, through the normalizing effect of 
the extract on the cancer metabolic alterations and through 
the evidence of extract antitumoral activity due to its 
impact on signalling pathways of oncogenic significance. 
We found that artichoke leaf extracts (freeze-dried extract 
prepared as indicated in the methods section by the ABOCA 
company- http://www.aboca.com) severely affect in vitro 
and in vivo mesothelioma tumorigenicity. Indeed, the 
artichoke leaf extract significantly reduces cell proliferation 
and colony formation of diverse mesothelioma cell lines. 
It also promotes apoptosis and restrains mesothelioma cell 
migration and invasion. It also impairs engraftment and 
reduces tumor volume of xenografted mesotheliomas. These 
effects are similar to those induced by pemetrexed. Protein 
array analyses reveal that the artichoke leaf extract activates 
distinct set of proteins to those of pemetrexed or cisplatin that 
might be critical mediators of its antitumoral activities.
RESULTS
The artichoke leaf extract inhibits MPM cell 
growth and proliferation
We aimed first to test the effects of the artichoke 
extract on mesothelioma cell growth and proliferation. To 
this end, we treated MSTO-211H, MPP-89 and NCI-H28 
mesothelioma cell lines and untransformed mesothelial 
cells, HMC (Figure 1A–1C) with increasing concentrations 
(ranging from 3 to 200 μg/ml) of artichoke leaf extract for 
72 hrs. We determined the half-maximal concentration of 
growth inhibition (IC50) for the extract phytocomplex in 
MPM cells (Figure 1A–1C, Supplementary Table 1). We 
found that the artichoke extract inhibited cell viability in a 
dose dependent manner (Figure 1A–1C). Moreover, MSTO-
211H cells treated with the artichoke extract showed a 
change in the cellular morphology both in a short-term assay 
that in long term as showed in Supplementary Figure 1. 
In contrast, HMC cells were more resistant to the growth 
inhibitory effect of the artichoke extract (Figure 1A–1C). 
Next, we performed a colony-forming assay to evaluate 
the capability of mesothelioma cells to form colonies after 
the removal of the extract. We found that the artichoke leaf 
extract inhibited the colony forming ability of MSTO-211H, 
MPP-89 and NCI-H28 cells (Figure 1D–1F). Altogether 
these findings indicated that the artichoke leaf extract 
treatment is highly effective on cell proliferation and colony 
forming ability of mesothelioma cell lines.
The artichoke leaf extract induces apoptosis 
of MPM cell lines
The induction of apoptosis is a pivotal event for 
successful cancer treatment by natural agents. To this end, 
we assessed whether the artichoke leaf extract induced 
apoptosis of mesothelioma cell lines using different 
approaches. Cytofluorimetric analysis revealed that the 
artichoke extract induced the appearance of a subG1 peak 
in MSTO-211H and MPP-89 cells. This effect was dose-
dependent (Figure 2A–2D). Furthermore, cells treated 
with the artichoke leaf extract for 24 hrs became Annexin 
V-positive in a dose-dependent manner (Figure 2E–2F). 
We also found that the extract treatment led to increased 
cleavage of caspase 3, caspase7 and Parp (Figure 2G). 
Comet assay performed in MSTO-211H and in HMC cells 
revealed that Cisplatin (7, 5 μg/ml, for 20 h) treatment 
induced DNA damage of both cell lines (Supplementary 
Figure 2A, 2B). Interestingly, the exposure to the artichoke 
leaf extract, used at not apoptotic concentration, 3 μg or 
6 μg/ml, did not induce DNA damage (Supplementary 
Figure 2A, 2B) and reduced that induced by CDDP in 
HMC cells (Supplementary Figure 2A). Overall, these 
results clearly demonstrate that the artichoke leaf extract 
affects cell viability of MPM cell lines by inducing 
apoptosis.
The artichoke leaf extract severely impairs 
migration and invasion of mesothelioma 
cell lines
It has been previously reported that dietary phenolic 
acids, monophenols and polyphenols possess inhibitory 
properties against the invasive and metastatic behaviours 
of different cancer cells lines.
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To this end, we investigated whether the artichoke 
leaf extract impaired migration and invasiveness of MPM 
cell lines. First, we performed scratch wound closure assay 
(Figure 3A, 3B) in MPM cell lines treated with different, 
not apoptotic, concentrations of the extract. We found 
that the artichoke extract inhibited, in a time dependent 
manner, migration of MSTO-211H and MPP89 as wound 
closure occurred slower than that of the control cells (Figure 
3A–3B). As matter of fact, the artichoke leaf extract at the 
concentration of 6 μg/ml and 12 μg/ml inhibited MSTO-
211H cells migration of 50% and 35% respectively as 
well as in MPP89 cell line (Figure 3A–3B). Second, we 
performed invasion assay in MSTO-211H cells using a 
24-well chamber with a non-coated 8-mm pore size filter 
in the presence of different concentrations of extract (6 μg 
and 12 μg/ml). As shown in figure 3C, the artichoke leaf 
extract markedly reduced the invasion of MSTO-211H cells. 
Altogether these results indicated that the artichoke extract 
inhibited migration and invasion of mesothelioma cell lines.
The artichoke leaf extract affects in vivo 
tumor growth
We aimed to assess in vivo the antitumoral effects 
of the extract. First, we evaluated whether the artichoke 
leaf extract could affect the engraftment of MSTO-
211H cells. To this end, MSTO-211H cells were treated 
for 24 hrs with vehicle or artichoke extract at 50 μg/
ml. Cell suspensions were subcutaneously injected into 
CD1 mice. As shown in figure 4A, cells pre-treated 
with the extract engrafted less efficiently than vehicle-
treated cells when inoculated into CD1 mice. We next 
evaluated the efficacy of the extract to inhibit the 
growth of xenografted mesotheliomas subcutaneously 
implanted in CD1 nude mice. To this end, CD1 mice 
were subcutaneously transplanted with MSTO-211H 
(2 × 106). At the evidence of tumor progression, 
mice were randomly divided in five different groups 
(n = 6) and were beverage with vehicle or artichoke leaf 
Figure 1: The artichoke leaf extract strongly affects the growth of MPM cells in a dose dependent manner. A, B, C. 
Viability of MPM cells (MSTO-211H, MPP89, NCI-H28) and normal untransformed mesothelial cell line (HMC) treated for 72 hrs with 
Cynara scolymus leaf extracts. The IC-50 value was indicated by a dotted line in each panel. Data are represented as mean +/– SD. Statistics 
(t-test): p < 0.05. (D, E, F). Colony forming assay. Histograms showing average colony counts from duplicate experiments. Bars indicate 
the average of three independent experiments. Statistics (t-test): p < 0.05.
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extract at different concentrations (25, 50 and 75 mg/ml) 
in drinking water (Table 2). Dietary feeding of the 
artichoke leaf extract for 3 weeks reduced significantly 
and dose dependent the growth of xenografted 
mesothelioma tumors (Figure 4B). This effect was 
similar to that induced by PMTX, a drug commonly 
employed in the treatment of mesothelioma (Figure 4B). 
To evaluate the proliferation index xenografted tumors 
were stained for Ki67 expression. Strikingly, we found 
that xenografted tumors derived from the extract treated 
mice exhibited significantly lower Ki67 expression than 
those treated with vehicle (Figure 4C, 4D). We also 
found that artichoke leaf extracts sensitized MSTO-211H 
and NCI-H28 mesothelioma cell lines to pemetrexed-
induced cell killing (Supplementary Figure 3A-B). 
Similarly, artichoke leaf extract at 75 mg/ml potentiated 
the antitumoral effect of pemetrexed on tumor volume 
of xenografted tumors (Supplementary Figure 3C). 
Altogether these findings indicate that the artichoke leaf 
extract can affect in vivo the growth of mesothelioma 
cell lines.
Artichoke leaf extract induces changes in 
metabolic profiles of MSTO-211H cells
Since metabolic alterations are among the hallmarks 
of a cancer cell we aim to assess whether the artichoke 
leaf extract could affect the metabolism of MSTO-211H 
cells. 1H-NMR metabolomics profiles of MSTO-211H cell 
culture media displayed significant differences between 
artichoke-treated and vehicle-treated cells. Initially, we 
explored the NMR data through an unsupervised approach 
such as Principal Component Analysis (PCA) carried out 
on a dataset of treated and untreated medium samples. 
Figure 2: The artichoke leaf extract induces apoptosis of MPM cells. A, B, C, D. Percentage of subG1 cell population of MPM 
cells (MSTO-211H and MPP-89) treated with the indicated doses of the artichoke extract for 48 or 72 hrs. Error bars represent mean +/– SD. 
Statistics (t-test): p < 0.05. E, F. Histograms showing the percentage of Annexin V+/PI- over vehicle. MPM cells (MSTO-211H, MPP-89) were 
treated at the indicated doses of the artichoke extract for 24. Error bars represent mean +/– SD. Statistics (t-test): p < 0.05. G. Representative 
protein gel blot of whole cell lysates obtained from MSTO-211H and MPP-89 cell lines treated for 24 hrs with 100 μg/ml of artichoke leaf 
extract and stained with anti-cleaved parp, anti-caspase-3 and anti-caspase-7 antibodies. Actin staining was used as loading control.
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The results reported in Figure 5A highlighted significant 
differences between the two groups on PC1 (p = 0.013). 
Subsequently, to identify the variables (metabolites) that have 
a major contribution to the discrimination between samples, 
we analyzed the loadings values from O-PLS-DA with a 
threshold of 0.8 (Figure 5B, 5C). LV1 included the following 
variables with the highest correlation levels: 3-methyl-2-
oxovalerate, acetate, N-acetyl groups, glutamax and succinate 
with positive loadings and arginine, pyruvate, tyrosine and 
phenylalanine with negative loadings. Therefore, considering 
the net balance of these metabolites, LV1 indicated that 
artichoke extract induced higher consumption of arginine, 
pyruvate, tyrosine and phenylalanine as well as a lower 
consumption of glutamax and succinate. Moreover, artichoke 
extract-treated cells exhibited higher production of 3-methyl-
2-oxovalerate, acetate and N-acetyl groups than vehicle-tread 
ones. This suggests that exposure to artichoke leaf extract 
mainly affected the citrate cycle (TCA cycle), arginine and 
proline metabolism, glutamine and glutamate metabolism, 
alanine, aspartate tyrosine metabolism and phenylalanine 
metabolism (Table 3).
The artichoke leaf extract antitumoral activity 
impinges on different signalling pathways
Since the artichoke extract appears to exert broad 
anti-tumoral effects on mesothelioma cell lines, we aimed 
to assess which signalling pathways might be involved. 
To this end, we performed a phospho-antibody array 
containing 1318 antibodies representative of key proteins 
involved in over than 30 signalling pathways altered in 
cancer among which proliferation, apoptosis, invasion, 
migration, metabolism and angiogenesis. MSTO-211H 
cells were treated for 24 hrs with the artichoke extract 
(50 μg/ml) or vehicle and the derived protein lysates were 
used to probe the antibody array. The heatmap shown 
in figure 6A represented the signal intensities of those 
proteins whose levels of expression or phosphorylation 
Figure 3: The artichoke leaf extract impairs the migration and invasion of MPM cells. A, B. Left side: representative 
micrographs of wound healing closure assays from MSTO-211H and MPP-89 cells treated for 36 hrs with 12, 5 μg/ml of artichoke leaf 
extract. Right side: histogram showing the healing closure efficiency of the cells treated with vehicle or the artichoke extract (6 μg and 
12 μg) after different times of treatment (0, 12, 24 and 36 hrs). Bars indicate the average of three independent experiments. Statistics (t-test): 
p < 0.05. C. Percentage of invading cells over vehicle. MSTO-211H cells were treated at the indicated doses of extract. Error bars represent 
mean +/– SD. Statistics (t-test): p < 0.05.
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were changed upon the artichoke leaf extract treatment. 
Among them, we found a group of proteins, which 
included p70S6k (phospho-Ser 418), NMDAR1 
(Ab-897), CAMK1-a (Ab-177), HDAC6 (phospho-Ser22), 
ACK1 (phosphoTyr284), p38 MAPK (phosphor Tyr-182) 
that were upregulated and phosphorylated upon the extract 
treatment compared to vehicle (Figure 6C). Strikingly, the 
artichoke leaf extract treatment activated key proteins such 
as p53, BAX p38, and Caspase 3 leading to apoptosis and 
downregulated survival and pro-tumorigenic factor among 
which c-Abl, STAT1, AKT, and VEGFR2 (Figure 6C) 
[37] [38]. By comparing the pattern of modulated proteins 
in MSTO-211H cells treated with Pemetrexed or Cisplatin 
we found that the artichoke extract modulated distinct 
and common sets of proteins when compared to the two 
drugs respectively (Figure 6B and Table 4). Among the 
proteins upregulated by the artichoke treatment, GSK 3a-β 
(Ab-216/279) appear to be pivotal components of multiple 
signalling pathways such PI3K/PTEN/AKT/mTORC1, 
Ras/Raf/MEK/ERK, Hedgehog, Notch and WNT. Since 
Table 1: Artichoke leaf extract components
Classes of Compounds Levels found in Artichoke 
freeze-dried extract
PolyPhenols (%) total
of which lignins total
of which tannins total
of which Caffeoylquinic acid derivatives total
of which Chlorogenic acid
of which phenypropanoid derivatives total
of which phenols and phenolic acids total
of which flavonoids total
of which salicilates total
34.251
1.98
5.96
10.33
4.07
7.01
0.703
8.27
0.001
Terpenes (%) total
of which Cynaropicrin
1.5
1.5
Organic Acids (%) total 6.3
Protein (%) total
of which water soluble proteins
5.6
5.6
Amino Acids fre (%) total 0.53
Polysaccharides (%) total
of which soluble dietary fiber
of which Insoluble dietary fiber
1.7
0.8
0.9
Saccharides (%) total
of which monosaccharides
Fructose
Glucose
of which disaccharides
Sucrose
of which fructo-oligosaccharides
24.69
2.58
8.02
8.89
5.2
Fats (%) total 0.087
Phytic acid (%) total 0.45
Minerals (Oligo, micro 
and macroelements) (%) total 9.5
Different classes of compounds present in the artichoke whole phytocomplex are reported. The phytocomplex is derived 
from artichokes (Cynara scolymus).
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aberrant activation of the WNT signalling pathway plays 
a role in mesothelioma tumorigenesis we investigated 
whether the treatment with the artichoke extract of MPM 
cell lines modulated the expression of diverse components 
of this pathway. We found that the artichoke leaf extract 
reduced β-catenin nuclear staining in two mesothelioma 
cell lines (Figure 7A–7B). This paired with the reduced 
expression of well-known β-catenin target genes such 
as LEF1, FGF8, COX2, MMP2 and VEGF transcripts 
(Figure 7C) [39]. Altogether these findings highlight the 
possibility that the broad antitumoral activities of the 
artichoke leaf extract on mesothelioma cell lines might 
occur through the modulation of diverse signalling 
pathways commonly altered in human cancers.
DISCUSSION
Malignant pleural mesothelioma is an extremely 
rare, highly lethal tumor: mesothelioma is highly resistant 
to current chemotherapeutic agents, thus the disease-
free-survival of the treated patients is very poor. Here 
we investigated whether, a phytocomplex derived from 
Artichoke leaves extracts, affects malignancy of pleural 
mesothelioma. It has been previously reported that 
artichoke phenol extracts can promote apoptosis and 
impair invasiveness of different cancer cell lines [34–36]. 
We found that the artichoke extract exerts in vitro and 
in vivo a broad anti-tumoral effect by strongly affecting 
MPM growth, migration and invasion. Next-generation 
sequence technologies have tremendously contributed 
to decipher tumor landscape and to dissect tumor 
heterogeneity. This has further established that cancer is 
the consequence of a broad array of genetic and epigenetic 
alterations. Modern drugs in the form of single-chemical 
entities have been successful in the treatment of acute 
conditions such as infectious diseases. Drug action is 
fast and predictable, leading to a favourable resolution 
of a critical situation in a short period of time. The 
situation is markedly different when treating complex 
chronic conditions such as cancer, type 2 diabetes and 
cardiovascular diseases. In particular considering cancer 
development, carcinogenesis process is multistep (that 
is, it results from accumulated genetic and epigenetic 
alterations), multipath (that is, multiple functional 
pathways are involved, such as self-sufficiency in growth 
signals, insensitivity to anti-growth signals, apoptosis 
Table 2: Scheme of treatment. 
Group n° of 
animals
Cell 
line
n° of 
cells
via Volume Treat. 
starting
Treat. A Treat. 
admin
Treat. 
schedule
Treat. B Treat. 
admin.
Treat. 
schedule
Group 1 6 MSTO 2*10^6 SC 0.2 ml (Matrigel) -
Group 2 6 MSTO 2*10^6 SC 0.2 ml (Matrigel)
After 
tumor 
appearance
- Artichoke 
(20 ug/ml)
OS drinkable water
Group 3 6 MSTO 2*10^6 SC 0.2 ml (Matrigel)
After 
tumor 
appearance
- Artichoke 
(50 ug/ml)
OS drinkable water
Group 4 6 MSTO 2*10^6 SC 0.2 ml (Matrigel)
After 
tumor 
appearance
- Artichoke 
(75 ug/ml)
OS drinkable water
Group 5 6 MSTO 2*10^6 SC 0.2 ml (Matrigel)
After 
tumor 
appearance
Pemetrexed 
(100 mg/kg)
IP
5 
consecutive 
days
Group 6 6 MSTO 2*10^6 SC 0.2 ml (Matrigel)
After 
tumor 
appearance
Pemetrexed 
(100 mg/kg)
IP
5 
consecutive 
days
Artichoke 
(20 ug/ml)
OS drinkable water
Group 7 6 MSTO 2*10^6 SC 0.2 ml (Matrigel)
After 
tumor 
appearance
Pemetrexed 
(100 mg/kg)
IP
5 
consecutive 
days
Artichoke 
(50 ug/ml)
OS drinkable water
Group 8 6 MSTO 2*10^6 SC 0.2 ml (Matrigel)
After 
tumor 
appearance
Pemetrexed 
(100 mg/kg)
IP
5 
consecutive 
days
Artichoke 
(75 ug/ml)
OS drinkable water
CD1 mice were subcutaneously transplanted with MSTO-211H (2 × 106). At the evidence of tumor progression (when tumor 
volume reached 60 mm3) mice were randomly allocated in placebo and in the artichoke leaf extract-treated groups as described in 
the table. A control group of mice was intraperitoneally injected with Pemetrexed at the dose of 100 mg/kg for five consecutive days
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evasion, limitless replicative potential, tissue invasion and 
metastasis and sustained angiogenesis), and multifocal 
(both multiclonal - e.g., field cancerization - and clonal 
expansion leading to intraepithelial spread). More than 
250 population-based studies, including case–control and 
cohort studies, indicate that people who eat about five 
servings of fruit and vege day have approximately half 
the risk of developing cancer, particularly cancers of the 
digestive and respiratory tracts, of those who eat fewer 
than two servings. The NCI has identified about 35 plant-
based foods that possess cancer-preventive properties. 
These include garlic, soybeans, ginger, onion, turmeric, 
tomatoes and cruciferous vegetables (for example, 
broccoli, cabbage, cauliflower and Brussels sprouts). 
Thus, the plants contain numerous substances, some 
of them pharmacologically active other inert but still 
potentially interacting with the active ones to potentiate 
the effectiveness as anticancer agents. The effectiveness 
as anticancer agent of a given plant could be endowed 
in its complexity (number of composing substances) 
coupled with multi-targeting activity. In aggregate this 
might allow concomitant untangling of diverse cancer 
pathways. Congruently, both metabolomics and antibody 
array analysis of MPM cells revealed that the artichoke 
leaf extract affects concomitantly different signalling 
pathways. We found that the extract affects β-catenin 
nuclear expression which pairs with the downregulation of 
the expression of its target genes such as LEF-1, FGF18, 
COX-2, MMP2 and VEGF. It was previously shown that 
direct targeting of β-catenin sensitizes mesothelioma cell 
lines to the treatment with cytotoxic drugs [40]. WNT 
is together with RAS, PI3K, Hippo and BCL among 
those pathways that are mostly altered in mesotheliomas 
[41]. We also found that the artichoke extract induces 
Figure 4: The artichoke leaf extract inhibits in vivo mesothelioma tumor growth. A. Artichoke extract inhibits engraftment of 
MSTO-211H cells. Suspensions of 2 × 106 MSTO-211H cells were pre-treated with either vehicle or the artichoke leaf extract (50 μg/ml) 
for 24 hrs and subcutaneously injected into CD1 mice as described in Material and Methods. No further treatment was given to mice. 
Horizontal bars represent the average tumor volume of the vehicle (n = 6) and the artichoke extract (n = 6) treated engrafted tumors. 
Tumors were collected 24 days after MSTO-211H cells injection. Statistics (t-test): p < 0.05. B. The artichoke leaf extract beverage inhibits 
in vivo mesothelioma tumor progression. Tumour volumes of mice (n = 6) treated with either vehicle, pemetrexed or the artichoke extract 
in drinking water are reported. Statistics (t-test): p < 0.05. C. Representative micrographs of the excised tumours stained with anti-Ki-67 
antibody. Scale bar, 100 μm. D. Histograms showing the percentage of Ki-67 positive nuclei scored in seven fields randomly chosen for 
each tumours. Statistics (t-test): p < 0.05.
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Figure 5: Metabolic response of MSTO-211H cell lines to the artichoke leaf treatment. PCA A. and O-PLS-DA B. models 
built on the 1H-NMR dataset of media samples from the artichoke extract-treated and vehicle-treated MSTO-211H cell cultures. The score 
plots show the metabolic differences between the two cell groups. Panel C shows the fold changes relative to vehicle-treated samples 
(means +/– SD for three independent experiments; (t-test): p < 0.05) of the most discriminant metabolites between the two groups from the 
O-PLS-DA model. 3-MOV, 3-Methyl-2-oxovalerate (p); Arg, arginine (c); Ac, acetate; N-Acetyl, group of N-acetyls; Glutamax, glutamax 
(c); Pyr, pyruvate (c ); Suc, succinate; Tyr, tyrosine (c); Phe, phenylalanine (c). “c” and “p” for each metabolite indicate consumption or 
production, respectively.
Table 3: Metabolic pathways perturbed by the artichoke leaf extract in MSTO-211H cells as 
determined by analysis of OPLS-DA loadings
Metabolite Artichoke leaf extract 
vs. vehicle
Kegg Related Pathways*
3-Methyl-2-oxovalerate higher production Valine, leucine and isoleucine degradation
Arginine higher consumption
Arginine and Proline metabolism
Alanine, aspartate and glutamate metabolism
Glycine, serine and threonine metabolism
Citrate cycle (TCA cycle)
Group of N-acetyls higher production
Arginine and proline metabolism
Amino sugar and nucleotide sugar metabolism
Alanine, aspartate and glutamate metabolism
Acetate higher production
Glycolysis/Gluconeogenesis
Pyruvate metabolism
Fatty acid metabolism
(Continued )
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Metabolite Artichoke leaf extract 
vs. vehicle
Kegg Related Pathways*
Glutamax lower consumption
D-Glutamine and D-glutamate metabolism
Purine metabolism
Pyrimidine metabolism
Alanine, aspartate and glutamate metabolism
Arginine and Proline metabolism
Pyruvate higher consumption
Pyruvate metabolism
Citrate cycle (TCA cycle)
Glycolysis
Pentose phosphate pathway
Succinate lower consumption
Citrate cycle (TCA cycle)
Oxidative phosphorylation
Alanine, aspartate and glutamate metabolism
Tyrosine metabolism
Phenylalanine metabolism
Carbon metabolism
Tyrosine higher consumption Tyrosine metabolism
Phenylalanine higher consumption Phenylalanine metabolism
*The metabolites are mapped to their respective biochemical pathways as delineated in the Kyoto Encyclopedia of Genes 
and Genomes (Release 69.0, January 1, 2014; KEGG, http://www.genome.jp/kegg).
Figure 6: Phosphoprotein analysis of MSTO-211H cells treated with the artichoke leaf extract. A. Heatmap overall 
intensities of protein and phospho-protein level of spotted 1318 proteins, after 24 hrs of treatment with vehicle or the artichoke extract 
(50 μg/ml). Red and blue shadings indicate high and low or undetectable protein levels respectively. B. Venn diagram showing the number 
of proteins and phospho-proteins whose result deregulated after 24 hrs of treatment with the artichoke extract (50 μg/ml), cisplatin (CDDP, 
8 μM) or pemetrexed (PMTX, 30 μM). C. List of all proteins and phospho-proteins that result deregulated after 24 hrs of artichoke extract 
treatment. Red and blue colours indicate up and down regulation respectively.
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Table 4: List of deregulated or phosphorylated proteins upon CDDP, PMTX or artichoke leaf 
extract treatment. The list of proteins whose result induced or downregulated by Cisplatin, Pemetrexed 
or the artichoke extract treatment compared to the vehicle is shown. In italics are reported the proteins 
which were modulated in more than one treatment
Pemetrexed Artichoke leaf extract Cisplatin
UP DOWN UP DOWN UP DOWN
-PKC theta (Ab-538)
-NFkB-p105/p50 
(Phospho-Ser337)
-LYN (Ab-507)
-MAPKAPK2 
(Ab-334)
-FGFR1 (Ab-654)
-Abl1 (Ab-204)
-DAXX (Ab-668)
-IKK-a/b 
(Ab-176/177)
-RAD52 (Ab-104)
-Merlin (Ab-10)
-Rb (Phospho-Ser780)
-MAPKAPK2 
(Phospho-Thr334)
-Ephrin B1/B2/B3 
(Phospho-Tyr324)
-HCK (Ab-410)
-DAXX 
(Phospho-Ser668)
-AKT1 (Ab-129)
-CD32 
(FcgammaRIIb) 
(Ab-292)
-NFkB-p65 
(Phospho-Ser468)
-NFkB-p100 
(Phospho-Ser872)
-RapGEF1 
(Phospho-Tyr504)
-FLT3 
(Phospho-Tyr969)
-BAX (Ab-167)
-HDAC1 (Ab-421)
-Caspase-3 (Ab-150)
-Mst1/Mst2 (Ab-183)
-p53 (Phospho-Ser9)
-SREBP-1 
(Phospho-Ser439)
-PFKFB2 
(Phospho-Ser483)
-CASP1 (Ab-376)
-GRB10 (Ab-67)
-Tyrosine Hydroxylase 
(Phospho-Ser31)
-PAK2 (Ab-192)
-Ezrin 
(Phospho-
Tyr478)
-EPB41 
(Ab-
418/660)
-Dok-1 
(Phospho-
Tyr362)
-HDAC6 
(Phospho-Ser22)
-ACK1 
(Phospho-Tyr284)
-P38 MAPK 
(Phospho-Tyr182)
-P70S6K (Phospho-
Ser418)
-GSK3a-b 
(Ab-216/279)
-CaMK1-a (Ab-177)
-NMDAR1 (Ab-897)
-Trk A (Phospho-
Tyr791)
-eNOS (Phospho-
Ser1177)
-BAX (Ab-167)
-P38 MAPK (Ab-322)
-Caspase-3 (Ab-150)
-CD19 (Ab-531)
-Mst1/Mst2 (Ab-183)
-p53 (Phospho-Ser9)
-SREBP-1 
(Phospho-Ser439)
-MAP3K7/TAK1 
(Ab-439)
-PFKFB2 
(Phospho-Ser483)
-CASP1 (Ab-376)
-GRB10 (Ab-67)
-’Tyrosine 
Hydroxylase 
(Phospho-Ser31)
-IkB-alpha 
(Phospho-Ser32/36)
-PAK2 (Ab-192)
-Histone H3.1 
(Phospho-Ser10)
-HSL (Phospho-
Ser552/563)
-Hsp90 co-
chaperone Cdc37 
(Phospho-Ser13)
-AKT (Phospho-
Ser473)
-PKA CAT 
(Phospho-
Thr197)
-DAB1 (Phospho-
Tyr220)
-VEGFR2 
(Phospho-
Tyr1059)
-AKT1 (Ab-308)
-EPHB1/2 (Ab-
594/604)
-Opioid Receptor 
(Ab-375)
-Amyloid beta 
A4 (Phospho-
Thr743/668)
-c-Abl (Phospho-
Tyr412)
-COT (Phospho-
Thr290)
-KSR (Phospho-
Ser392)
-Zap-70 
(Phospho-Tyr493)
-STAT1 
(Phospho-Ser727)
-ACC1 (Phospho-
Ser79)
-CDC25B 
(Phospho-Ser353)
-BTK (Phospho-
Tyr550)
-NFkB-p65 
(Phospho-Ser468)
-Dok-1 
(Phospho-Tyr362)
-ATP-Citrate 
Lyase 
(Phospho-Ser454)
-VEGFR2 
(Phospho-
Tyr1054)
-HER2 (Ab-877)
-P38 MAPK 
(Ab-180)
-Ras-GRF1 
(Phospho-Ser916)
-Smad2 (Ab-245)
-RapGEF1 
(Phospho-Tyr504)
-FLT3 
(Phospho-Tyr969)
-BAX (Ab-167)
-P38 MAPK 
(Ab-322)
-Caspase-3 
(Ab-150)
-CD19 (Ab-531)
-Mst1/Mst2 
(Ab-183)
-p53 
(Phospho-Ser9)
-SREBP-1 
(Phospho-Ser439)
-MAP3K7/TAK1 
(Ab-439)
-PFKFB2 
(Phospho-Ser483)
-CASP1 (Ab-376)
-GRB10 (Ab-67)
-Tyrosine 
Hydroxylase 
(Phospho-Ser31)
-IkB-alpha 
(Phospho-
Ser32/36)
-PAK2 (Ab-192)
-Smad1 (Ab-465)
-Cytokeratin 18 
(Ab-52)
-HER2 
(Phospho-Tyr877)
-EGFR 
(Phospho-
Tyr1092)
-G3BP-1 
(Phospho-Ser232)
-MEK1 
(Phospho-Ser298)
-Smad3 (Ab-213)
-Tau (Phospho-
Ser356)
-Tau 
(Phospho-
Thr205)
-Androgen 
Receptor 
(Phospho-Ser213)
-NMDAR1 
(Phospho-Ser897)
-PLCG1 
(Phospho-
Tyr1253)
-Rb (Phospho-
Ser807)
-Synaptotagmin 
(Phospho-Ser309)
-p21Cip1 
(Ab-145)
-Smad1 
(Phospho-Ser465)
-VAV2 (Ab-142)
-Dok-1 
(Phospho-Tyr362)
-ATP-Citrate 
Lyase 
(Phospho-Ser454)
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phosphorylation of the tumor suppressor protein p53 on 
Ser9. Saito et al., have shown that phosphorylation of p53 
on Ser 46, as well as on Ser 9 was dependent from ATM 
protein kinases in response to ionizing radiation [42]. This 
led to p53 stabilization, transcriptional activation and 
induction of apoptosis. ATM-mediated phosphorylation 
on Ser 15 and at nearby residues including Ser 6 and Ser 
9 enhanced p53 apoptotic activities. Piccolo’s group has 
shown that p53 phosphorylation on Ser 9 was instrumental 
for the activation of the TGF-β cytostatic program [43]. 
AKT/PKB is frequently activated in tumors and is an 
important player for signalling pathways that regulate 
growth and survival. Fully active AKT/PKB mediates 
numerous cellular functions including metabolism, 
angiogenesis, growth, proliferation, survival, protein 
synthesis, transcription, and apoptosis. We found that 
artichoke leaf extract reduced both protein levels of 
AKT1 and of its phosphorylation at Ser473 that enables 
fully activation of the signalling axis involving insulin 
receptor, IRS and PI3 kinase. This pairs with our 
metabolomics data indicating that artichoke leaf extract 
affects the citrate cycle (TCA cycle), arginine and proline 
metabolism, glutamine and glutamate metabolism, 
alanine, aspartate tyrosine metabolism and phenylalanine 
metabolism (Table 3). Thus, artichoke leaf extract might 
impact on crucial metabolic pathways that are aberrantly 
activated in human cancers. Altogether these evidences 
contribute to categorize artichoke leaf extract as a natural 
product with broad antitumoral activity on malignant 
pleural mesothelioma. Due to the evidence that the 
signalling pathways altered in mesothelioma and affected 
by artichoke leaf extracts are common to other human 
malignancies we might expect that cynara scolymus could 
exert antitumoral effects on other types of human cancers 
(Supplementary Figure 5). Data shown in figure 1A-F 
and Supplementary Figures 2A-B and 3A-C provide in 
vitro and in vivo evidence for a co-treatment of artichoke 
leaf extracts with either cisplatin or pemetrexed. Indeed, 
artichoke leaf extract, unlike cisplatin that provoked DNA 
damage to both mesothelial (HMC) and mesothelioma 
cell lines, exerted a more pronounced apoptotic effects 
on MPM cell lines than HMC. Interestingly artichoke 
leaf extracts reduced DNA damage of HMC cells upon 
cisplatin treatment, thereby suggesting that its co-treatment 
with either cisplatin or pemetrexed not only potentiates 
their antitumoral effects but might also confers selectivity 
toward tumor cells. Natural products are also the leading 
compounds for chemopreventive strategies. This is mainly 
Figure 7: The artichoke leaf extract downregulates Wnt/β-catenin signalling. A-B. Histograms showing the percentage of 
β-catenin positive nuclei/total nuclei of MSTO-211H A and MPP-89 cells B treated for 24 hrs with either vehicle or the artichoke extract 
(50 μg/ml). Bars indicate the average of three independent experiments. Statistics (t-test): p < 0.05. C. Q-PCR for the expression of the 
indicated Wnt/β-catenin target genes from either vehicle or artichoke leaf extract-treated MSTO 211H cells (50 μg/ml, 24 hrs). Bars indicate 
the average of three independent experiments. Statistics (t-test): p < 0.05.
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based on the evidence that are well tolerated and have 
no or very minimal side effects on the subjects enrolled 
in chemoprevention trials. MPM is an occupational 
disease with a latency up to 40–50 years that represents 
an extraordinary time window for a chemopreventive 
approach. Indeed, a Phase II clinical trial (NCT02076672) 
aiming to investigate the anti-cancer activity of artichoke 
leaf extract in an asbestos-exposed population is currently 
enrolling participants in Ontario.
MATERIALS AND METHODS
Cell lines
The human MPM cell lines MSTO-211H, NCI-H28, 
MPP89 were purchased from the ATCC (Rockville, MD). 
HMC, human mesothelial cells, were purchased from 
Tebu-Bio (Le Perray en- Yvelines, France). All MPM cell 
lines, were cultured as monolayers at 37°C and 5% CO2 
in DMEM/F12 + GLUTAMAX (InVitrogen, Carlsbad, 
CA) supplemented with 10% non-heat inactivated FBS 
(Gibco, Life Technologies, USA) and 0, 5 Unit/ml insulin 
(Humulin, Eli Lilly and Company, Indiana, USA), while 
HMC were cultured in Mesothelial cell basal medium 
(Zen-Bio, Research Triangle Park, NC).
Extraction procedure and phytochemical 
characterization
Frozen artichoke leaf samples were extracted (DER 
from 5 to 6:1) by hydro-alcoholic procedure (ETOH 50%). 
The phytocomplex consists of a partially purified mixture 
of polyphenolic compounds and terpenes extracted from 
artichoke (Cynara scolymus L.) enriched in caffeoylquinic 
acids, chlorogenic acid and cynaropicrine. It is a pending 
Aboca’s patent (RM2014A000685). It was submitted to a 
complete characterization of the composition by means of 
metabolomic analysis (LC-ESI/MS) (as previously described 
[28] and by quantitative analysis of caffeoylquinic acids 
(SFM), chlorogenic acid (HPLC-UV) and cynaropicrine 
(HPLC-UV). The complete chemical classes of compounds 
(phenols, terpenes, fats, proteins, amino acids, minerals, 
polysaccharides, etc.) addictionally analysed and presents in 
the phytocomplex are listed in Table 1.
Chemicals and antibodies
Artichoke capsules (Aboca, Sansepolcro, Italy); 
Pemetrexed (ALIMTA, Eli Lilly and Company, Indiana, 
USA) and Cisplatin (Pfizer Pharmaceuticals Group, 
New York, USA) were dissolved according to the 
manufacturer’s instructions. The following primary 
antibodies were used: anti-cleaved PARP (Asp214) (Cell 
Signaling, # 9541); anti-caspase 7 (Cell Signaling, #9492); 
anti-caspase 3 (Enzo life Science, #31A1067); anti-beta 
actin (A-2228, SIGMA); β-catenin antibody (clone 
CAT-5H10, # 18–0226. Zymed). Secondary horseradish 
peroxidase-conjugated was purchased from Santa Cruz; 
secondary antibody for immunofluorescence Alexa Fluor 
594 (mouse) conjugated was obtained from Molecular 
Probes (Inc, Eugene, OR, USA). ECL reagent (Amersham, 
GE Healthcare, Piscataway, NJ, USA) was employed for 
the chemo-luminescence detection. Annexin V FITC (0, 2 
μg/ml) (Abcam, ab-63556); DAPI staining (Sigma) was 
used for nuclear detection.
RNA processing and qRT-PCR
Total RNA from mesothelioma cell lines 
was extracted by using Trizol Reagent following 
manufacturer’s instructions (InVitrogen).
The first-strand cDNA was synthesized according 
to the manufacturer’s instructions (M-MLV RT kit, 
Invitrogen). Gene expression was measured by real-
time PCR using the FastStart SYBR Green Master Mix 
(Applied Biosytems) on a 7900HT instrument (Applied 
Biosystems). Sequences of qPCR primers are LEF-1 Fw: 
5′-AGCGAATGTCGTTGCTGAGTGTA-3′, Rv 5′-CT 
CTTGCAGACCAGCCTGGATAA-3′. FGF18 Fw: 5′- CT 
CTACAGCCGGACCAGTG-3′, Rv: 5′- CCGAAGGTGTC 
TGTCTCCAC-3′. ACTIN Fw: 5′-GGCATGGGTCAGA 
AGGATT-3′, Rv: 5′-CACACGCAGCTCATT GTAGA 
AG-3′. C-MYC Fw: 5′-CTCCTGGCAAAAGG TCAGA 
G-3′, Rv: 5-TCGGTTGTTGCTGATCTGTC-3′. COX2 
Fw: 5′- GAATGTTCCACCCGCAGTACA-3′, Rv: 
5′- GCATAAAGCGTTTGCGGTAC-3′. VEGF Fw 5′-CGA 
GGGCCTGGAGTGTGT-3′, Rv: 5′-CGCATAATCTGCAT 
GGTGATG-3′. CyclinD1 Fw: 5′-GCCCTCGGTGTCC 
TACTTC-3′, Rv: 5′-AGGAAGCGGTCCAGGTAGTT-3′. 
MMP2 Fw: 5′-AAGTCTGGAGCGATGTGACC-3′, Rw: 
5′-GAGTCCGTCCTTACCGTCAA-3.′
Cell viability assay
Cell viability of treated cells was assessed using 
ATPlite assay (Perkin Elmer, Massachusset, USA) 
accordingly to the manufacturer’s instructions. Cell 
viability tests were carried out to determine the efficacy 
of Cynara scolymus concentrations using different plant 
fractions and lot numbers. Cells (8 × 102 cells) were 
seeded in 96 well-plates and cultured for 24 hrs and treated 
for 72 hrs with Cynara scolymus leaf extracts. Each plate 
was evaluated immediately on a microplate reader (Expire 
Technology, Perkin Elmer).
Clonogenic assays
MPM cell lines were grown at 70% confluence and 
treated with Cynara scolymus leaf extracts or with vehicle. 
Sixteen hrs later, cells were detached and seeded at 600 
cells per 6 well into six-well dishes (Corning-Costar, 
Tewksbury, MA, USA) in drug-free media. Fresh media 
(25%) was added every three days. After 15–21 days, 
colonies were stained with crystal violet and colonies 
counted.
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Apoptosis detection
To determine the effect of artichoke leaf extracts on 
the cell cycle FACS analysis was carried out. For propidium 
iodide (PI) staining, cells were seeded in 6-well plates at 
a density of 104 cells/ml. After 24 hrs cells were treated 
with indicated plant extract concentrations for different 
time intervals. Floating and attached cells were harvested, 
washed in PBS, fixed in ice-cold ethanol (70% v/v) and 
stored at −20°C. For the analysis, cells were washed in PBS 
and incubated with RNase A (1 mg/ml) and PI (40 μg/ml) 
was added. For PI/Annexin V double staining treated cells 
were harvested and suspended in binding buffer (HEPES 
pH 7.4, CaCl2 2.5 mM, NaCl 140 mM). Aliquots of cells 
were incubated for 15 min with Annexin V FITC (0, 2 μg/
ml) (Abcam, ab-63556) and PI (5 mg/ml) (Invitrogen). For 
each FACS analysis, 3x 103 events for each sample were 
analyzed. Flow cytometry analyses were carried out with 
Easycyte 8HT (Guava, Millipore) followed by analysis 
using InCyte software (Millipore).
Transwell invasion assay
Migration assay was performed using a 24-well 
Boyden chamber with a non-coated 8-mm pore size filter in 
the insert chamber (BD Falcon, Franklin Lakes, NJ, USA). 
Cells were suspended in 0.5 ml DMEM/F12 media without 
containing FBS and seeded into the insert chamber. Cells 
were allowed to migrate for 24 hrs into the bottom chamber 
containing 0.5 ml of DMEM/F12 media containing 10% 
FBS in a humidified incubator at 37°C in 5% CO2. 
Migrated cells that attached to the outside of the filter were 
visualized by staining with DAPI and counted. The average 
number of cells per field was expressed as percentage of the 
control after normalizing for cell number.
Wound–healing migration assay
MPM cells were grown to 80% of confluence in 
6-well tissue culture plates and wounded with a sterile 
10-mL pipet tip to remove cells. PBS washing was used 
to remove loosely attached cells. The progression of 
migration was at photographed at different times under 
a light microscope. The number of cells migrated into the 
scratched area was calculated.
Comet assays
Cells were pre-treated with or without 3 μg or 6 μg/ul 
of Cynara scolymus for 16 hrs. After that, cells were 
treated or not with CDDP, 7.5 µg/ml, for 20 hrs. After 
treatment, cells were detached with trypsin and embedded 
in 1% low melting agarose (Sigma) in phosphate-buffered 
saline and spread onto microscopy slides coated previously 
with 1% agarose (Bio-Rad). Cells were lysed in the lysis 
solution (2.5 M NaCl, 100mM ethylenediaminetetraacetic 
acid, 10mM Tris base, 8 g/l NaOH, 1% Triton X-100, 
10% dimethyl sulfoxide) for 1 h at room temperature 
and then run in running solution (300mM NaOH, 1mM 
ethylenediaminetetraacetic acid, pH 13.0) for 30 min at 
25V and 250 mA. DNA was equilibrated with 0.4M Tris 
(pH 8.0) and slides were dried with methanol. DNA was 
stained with propidium iodide (Sigma) and pictures were 
taken using 63 × magnification at an Axiovert 200 M 
microscope and Axiovision acquisition program (Zeiss). 
At least 300 cells were scored for each slide.
Western blot analysis
Cell lysis was performed on ice for 30 min in NP40 
lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% 
NP-40, 1 mM EGTA, 1 mM EDTA) supplemented with 
protease and phosphatase inhibitors (5 mM PMSF, 3 mM 
NaF, 1 mM DTT, 1 mM NaVO4). Equal amounts of total 
proteins extracts (30 μg) were resolved by 8% denaturing 
SDS polyacrylamide gel electrophoresis (SDS-PAGE), 
and transferred for 2 hrs to polyvinylidene difluoride 
membrane. Membranes were blocked in 5% milk-
TBS-0.05% Tween 20 for 1 hour and incubated overnight 
with the specific primary antibodies (see chemicals and 
antibodies section).
Immunofluorescence microscopy
Briefly, MSTO-211H cells were seeded into eight-
chamber culture slides (BD Falcon). The next day, cells 
were rinsed with ice-cold PBS buffer and fixed with 4% 
paraformaldehyde for 10′ at room temperature and then 
permeabilized with 1% Triton X-100. The cells were 
incubated overnight with the indicated antibody. The day 
after, cells were washed with cold PBS three times for 3 min 
each and stained for 2 hrs with a secondary antibody Alexa 
488-conjugated goat anti-mouse IgG (Molecular Probes 
Cells) and counterstained with DAPI (40, 6-diamidino-2-
phenylindole, dihydrochloride). Cells were examined under 
a Zeiss LSM 510 laser scanning fluorescence confocal 
microscope (Zeiss, Wetzlar, Germany).
Sample preparation for NMR spectroscopy
Each medium sample (2 ml) was lyophilized, 
then dissolved in 700 μl of 1 mM TSP [sodium salt of 
3-(trimethylsilyl) propionic-2, 2, 3, 3-d4 acid], 10 mM 
sodium azide D2O phosphate buffer solution (pH = 7.4) 
and finally homogenized by vortex mixing for 1 min. After 
centrifugation (10 min, 10.000 RCF at 22°C), 600 μl of 
each resulting supernatant was transferred to a 5-mm 
NMR tube and used for the NMR analysis.
1H-NMR spectroscopy
2D 1H J-resolved (JRES) NMR spectra were 
acquired on a 500 MHz Varian/Agilent spectrometer 
(Agilent, Santa Clara, CA) using a double spin echo 
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sequence with 4 transients per increment for a total 
of 32 increments. These were collected into 16 k data 
points using spectral widths of 6 kHz in F2 and 40 Hz 
in F1. There was a 2.0 s relaxation delay. Each FID was 
Fourier transformed after a multiplication with sine-bell/
exponential function in the F2 dimension and a sine-bell 
function in the F1 dimension. JRES spectra were tilted 
by 45°, symmetrised about F1, referenced to TSP at dH 
= 0.0 ppm and the proton-decoupled skyline projections 
(p-JRES) exported using Agilent VNMRJ 3.2 software. 
Metabolites responsible for the separation between treated 
and untreated samples were identified using an in-house 
NMR database and Chenomx NMR suite v. 7.7 (Chenomx 
Inc., Alberta, Canada).
NMR spectra pre-processing treatment
The 1D skyline projections exported were aligned 
and then reduced into spectral bins with ranging from 
0.01 to 0.02 ppm by using the ACD intelligent bucketing 
method (1D NMR Manager software (ACD/Labs, Toronto, 
Canada). To compare the spectra, the integrals derived 
from the binning procedure were normalized to the total 
integral region, following exclusion of bins representing 
the residual water peak (4.33–5.17 ppm) and the TSP peak 
(0.5–0.5 ppm).
The resulting data was used as input for multivariate 
analysis: Principal Component Analysis (PCA and 
Orthogonal projections to latent structures discriminant 
analysis (OPLS-DA) were performed using SIMCA-P + 
version 12 (Umetrics, Umea, Sweden).
Phospho-protein profiling by the phospho 
explorer antibody microarray
The Phospho Explorer antibody microarray, which 
was designed and manufactured by Full Moon Biosystems, 
Inc. (Sunnyvale, CA), contains 1318 antibodies [44]. 
Each of the antibodies has two replicates that are printed 
on a coated glass microscope slide, along with multiple 
positive and negative controls (Supplementary Figure 4). 
The antibody array experiment was performed using Full 
Moon Biosystems, according to their established protocol. 
In brief, cell lysates obtained from MSTO-211H treated 
with the artichoke extract at 50 μg/ml or with Cisplatin 
at 8 μM or Pemetrexed at 30 μM of concentrations for 
24 hrs, were biotinylated with the antibody array assay kit 
(Full Moon Biosystems, Inc.). The antibody microarray 
slides were first blocked with a blocking solution (Full 
Moon Biosystems, Inc.) for 30 min at room temperature, 
rinsed with Milli-Q grade water for 3–5 min. The slides 
were then incubated with the biotin-labeled cell lysates in 
coupling solution (Full Moon Biosystems, Inc.) at room 
temperature for 2 hrs. The array slides were washed 4 to 
5 times with 1x Wash Solution (Full Moon Biosystems, 
Inc.) and rinsed extensively with Milli-Q grade water 
before detection of bound biotinylated proteins using 
Cy3-conjugated streptavidin. Each slide (containing six 
replicates) hybridized and Cy3 fluorescence acquired 
by microarray scanner with a scan resolution of 10 mm 
(Agilent Technologies). The images were quantified 
using Agilent Feature Extraction (AFE) software (Agilent 
Technologies). The fluorescence signal of each antibody 
was obtained from the fluorescence intensity of this 
antibody spot after subtraction of the blank signal (spot in 
the absence of antibody).
Statistical analysis
Bionformatic analysis was performed with Matlab 
(The MathWorks Inc.). Z score transformation was used 
to express the background corrected spot intensity values 
as unit of a standard deviation from the normalized 
mean of zero [45]. Features were selected basing on Z 
ratios calculated by taking the difference between the 
averages of the observed protein Z scores and dividing 
by the standard deviation of all the differences for 
that particular comparison. A Z-ratio that was higher 
than 1.96 was inferred as significant. Unsupervised 
Hierarchical Clustering was used to investigate clusters 
of samples. Pathway analysis was performed by DAVID 
program [46] [47].
EnSpire® cellular label-free platform
MSTO-211H cells were seeded in specially designed 
384- well plate with highly precise optical sensors able 
to measure changes in light refraction resulting from 
dynamic mass redistribution (DMR) within the cell’s 
monolayer. Change in the light refraction was indicated 
by a shift in wavelength.
Experimental animals and ethics statement
Xenograft transplantation
MSTO-211H cells were pre-treated with the 
artichoke extract (50 μg/ml) for 24 hrs. Suspensions 
of 2 × 106 MSTO-211H cells x mouse (n = 6) 
were subcutaneously injected in PBS 1x/Matrigel 
(BD Biosciences San Jose, CA, USA) into 6-weeks-old 
female CD1 mice (Charles River, Milan). Tumor volume 
was calculated by using the formula: V 1/2 x length 
x width2 (by electronic caliper).
Animal studies
CD1 mice were subcutaneously transplanted 
with MSTO-211H (2 × 106). At the evidence of 
tumor progression (when tumor volume reached 
60 mm3) animals were randomly divided in five groups. 
Drinking water and a complete pellet diet (GLP 4RF21, 
Mucedola) were supplied ad libitum. Three groups 
of mice (n = 6) were given the artichoke extract in 
drinking water at the following concentrations: 25, 
50 and 75 mg/ml, whereas mice of the control group 
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(n = 6) were given tap. In the last group, pemetrexed 
was injected intraperitoneally at the dose of 100 mg/
kg for five consecutive days. Body weight and clinical 
signs of the mice were checked every 3 days. All 
tumorigenicity assays were performed according to the 
guidelines set by the internal ethical committee. At the 
end of the experiment tumor masses were collected and 
fixed in 10% buffered formalin.
Immunoistochemical analysis
Formalin-fixed and paraffin-embedded 5 μm 
sections from mice tumor sections were stained with 
haematoxylin and eosin or stained with anti-ki67 antibody 
(ab15580, Abcam). Seven fields chosen randomly from 
each sample were scored.
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